HER2 amplification and overexpression are significantly correlated in mucinous epithelial ovarian cancer

Human Pathology

Volumn 45, Issue 4, 2014, Pages 810-816

  Chao, Wan Ru ^a   Lee, Ming Yung ^b   Lin, Wea Long ^a   Chen, Chi Kuan ^c   Lin, Jau Chen ^d   Koo, Chiew Loon ^a,e   Sheu, Gwo Tarng ^a   Han, Chih Ping ^a  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b PROVIDENCE UNIVERSITY   (Taiwan)

^c MACKAY MEMORIAL HOSPITAL   (Taiwan)

^d FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^e TUNGS' TAICHUNG METROHARBOR HOSPITAL   (Taiwan)

Author keywords

HER2; Mucinous epithelial ovarian cancer; Polysomy 17

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; ASIAN; CHROMOSOME 17; CLINICAL ARTICLE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY CARCINOMA; TAIWAN; TISSUE MICROARRAY; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATIONAL STUDY; DNA PROBE; IMMUNOASSAY; ONCOGENE NEU; TUMOR CELL;

HER2; MUCINOUS EPITHELIAL OVARIAN CANCER; POLYSOMY-17;

ADENOCARCINOMA, MUCINOUS; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION PROFILING; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2; TISSUE ARRAY ANALYSIS;

EID: 84896517962     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2013.11.016     Document Type: Article

References (21)

1. R.A. Soslow Histologic subtypes of ovarian carcinoma: an overview Int J Gynecol Pathol 27 2008 161 174 (Pubitemid 351450675)
2. W.Y. Chay, S.H. Chew, and W.S. Ong et al. HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer PLoS One 8 2013 e61565
3. R.I. Nicholson, J.M. Gee, and M.E. Harper EGFR and cancer prognosis Eur J Cancer 37 Suppl 4 2001 S9 S15
4. J.N. McAlpine, K.C. Wiegand, and R. Vang et al. Overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy BMC Cancer 9 2009 433
5. I. Rubin, and Y. Yarden The basic biology of HER2 Ann Oncol 12 Suppl 1 2001 S3 S8
6. A. García-Velasco, C. Mendiola, and A. Sánchez-Muñoz et al. Prognostic value of hormonal receptors, p53, ki67 and HER2/neu expression in epithelial ovarian carcinoma Clin Trans Oncol. 10 2008 367 371
7. C. Gravalos, and A. Jimeno HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target Ann Oncol 19 2008 1523 1529
8. Australia Roche Herceptin (trastazumab) product information http://www.roche-australia.com/fmfiles/re7229005/downloads/oncology/ herceptin-pi.pdf Last update 13 August 2012. Accessed 10 August 2013
9. M.S. Anglesio, S. Kommoss, M.C. Tolcher, B. Clarke, L. Galletta, and H. Porter Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas J Pathol 229 2013 111 120
10. C.K. Lin, W.L. Lin, and F.L. Chen et al. Assessing the impact of polysomy-17 on HER2 status as well as the correlations of HER2 status with prognostic variables (ER, PR, p53, Ki-67) in epithelial ovarian cancer: a tissue microarray study using immunohistochemistry and fluorescent in situ hybridization Int J Gynecol Pathol 30 2011 372 379
11. US Biomax OV2001, Ovarian cancer high-density (200 cases/200 cores) tissue array http://www.biomax.us/tissue-arrays/Ovary/OV2001 (Accessed at 20 Oct. 2013)
12. Y.J. Bang, E. Van Cutsem, and A. Feyereislova et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 28 2010 687 697
13. M. Hoopmann, K. Sachse, and M.M. Valter et al. Serological and immunohistochemical HER-2/neu statuses do not correlate and lack prognostic value for ovarian cancer patients Eur J Cancer Care (Engl). 19 2010 809 815
14. E.E. Grimm, R.A. Schmidt, P.E. Swanson, S.M. Dintzis, and K.H. Allison Achieving 95% cross-methodological concordance in HER2 testing: causes and implications of discordant cases Am J Clin Pathol 134 2010 284 292
15. I.S. Shergill, N.K. Shergill, M. Arya, and H.R. Patel Tissue microarrays: a current medical research tool Curr Med Res Opin 20 2004 707 712 (Pubitemid 38685016)
16. O.P. Kallioniemi, U. Wagner, J. Kononen, and G. Sauter Tissue microarray technology for high-throughput molecular profiling of cancer Hum Mol Genet 10 2001 657 662 (Pubitemid 32331572)
17. W.M. Hanna, J. Rüschoff, and M. Bilous et al. HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity Mod Pathol 2013 10.1038/modpathol.2013.103 (Epub ahead of print)
18. H. McCaughan, I. Um, S.P. Langdon, D.J. Harrison, and D. Faratian HER2 expression in ovarian carcinoma: caution and complexity in biomarker analysis J Clin Pathol 65 2012 670 671
19. J.A. Wilken, K.T. Webster, and N.J. Maihle Trastuzumab Sensitizes ovarian cancer cells to EGFR-targeted therapeutics J Ovarian Res. 3 2010 7
20. J. Alexandre, I. Ray-Coquard, and F. Selle et al. Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience Ann Oncol 21 2010 2377 2381
21. A. Gurung, T. Hung, J. Morin, and C.B. Gilks Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates Histopathology 62 2013 59 70